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Abstract
Background: Mammary tumours frequently develop in female domestic cats being highly malignant in a large
percentage of cases. Chemokines regulate many physiological and pathological processes including organogenesis,
chemotaxis of inflammatory cells, as well as tumour progression and metastasization. In particular, the chemokine/
receptor pair SDF-1/CXCR4 has been involved in the regulation of metastatic potential of neoplastic cells, including
breast cancer. The aim of this study was the immunohistochemical defininition of the expression profile of CXCR4
in primary and metastatic feline mammary carcinomas and the evaluation of the role of SDF-1 in feline mammary
tumour cell proliferation.
Results: A total of 45 mammary surgical samples, including 33 primary tumours (31 carcinomas and 2 adenomas),
6 metastases, and 4 normal mammary tissues were anlyzed. Tumor samples were collected from a total number of
26 animals, as in some cases concurrent occurrence of neoplasm in more than one mammary gland was observed.
Tissues were processed for standard histological examination, and all lesions were classified according to the World
Health Organization criteria. CXCR4 expression in neoplastic cells was evaluated by immunohistochemistry. The
level of CXCR4 immunoreactivity was semi-quantitatively estimated as CXCR4 score evaluating both the number of
positive cells and the intensity of staining. Six primary, fibroblast-free primary cultures were obtained from fresh
feline mammary carcinomas and characterized by immunofluorescence for CXCR4 and malignant mammary cell
marker expression. SDF-1-dependent in vitro proliferative effects were also assayed. CXCR4 expression was observed
in 29 out of 31 malignant tissues with a higher CXCR4 score observed in 4 out of 6 metastatic lesions than in the
respective primary tumours. In 2 benign lesions analyzed, only the single basaloid adenoma showed a mild
positive immunostaining against CXCR4. Normal tissue did not show CXCR4 immunoreactivity. CXCR4 score was
statistically significantly associated with the histological features of the samples, showing an increase accordingly
with the degree of neoplastic transformation (from normal tissue to metastatic lesions). Finally, in the primary
cultures obtained from 6 primary feline mammary carcinomas CXCR4 expression was detected in all cells and its
activation by SDF-1 in vitro treatment caused a significant increase in the proliferation rate in 5 out of 6 tumours.
Conclusions: These results indicate that malignant feline mammary tumours commonly express CXCR4, with a
higher level in malignant tumours, and, in most of the cases analysed, metastatic cells display stronger
immunoreactivity for CXCR4 than the corresponding primary tumours. Moreover, CXCR4 activation in primary
cultures of feline mammary carcinomas causes increase in the proliferative rate. Thus, SDF-1/CXCR4 system seems
to play a tumorigenic in feline mammary gland malignancy and in vitro cultures from these tumour samples may
represent an experimental model to investigate the biological and pharmacological role of this chemokinergic axis.
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Chemokines are small messengers with chemoattractant
function (chemotactic cytokines). They belong to a large
superfamily of peptides produced and secreted by differ-
ent cell types and classified in four groups (CC, CXC, C,
and CX3C) accordingly to structural determinants [1].
The complex chemokine system is involved in a wide
range of cell functions ranging from organogenesis to
malignancy. Chemokine activity is mediated by the acti-
vation of a family of specific G protein coupled receptors.
Chemokine receptor activation is mediated by coupling
to intracellular heterotrimeric G-proteins associated with
the inner surface of the plasma membrane [2]. Upon
ligand binding, chemokine receptors promote G protein
activation leading to the inhibition of cAMP synthesis
and the activation of phospholipase C that cleaves phos-
phatidylinositol (4,5)-bisphosphate (PIP2) into the second
messengers inositol triphosphate (IP3) and diacylglycerol
(DAG). DAG activates protein kinase-C (PKC), while IP3
induces the release of calcium ions from intracellular
stores. Several studies supported the role of chemokiner-
gic axis in physiological activities including organogenesis
[3], haematopoiesis [4], angiogenesis [5], homing of lym-
phocytes [6], immune response and inflammation [7].
Among CXC chemokine receptors, in the past years,
CXCR4 attracted great attention for its pleiotropic activ-
ity outside the immune system [8,9]. CXCR4 activity is
dependent on its interaction with its unique ligand: stro-
mal cell-derived factor-1 (SDF-1, also named CXCL12)
[10]. SDF-1 was recently reported to bind also a second
receptor CXCR7, which regulates very different cellular
activities [11] including tumor angiogenesis [12-14].
Beside regulation of Ca
++ homeostasis and PKC activa-
tion, CXCR4 also modulate ERK1/2 MAP kinase and Akt
activities through a paracrine/autocrine mechanism
[15,16]. The activation of all these signalling cascades
generates specific biological responses, such as chemo-
taxis, degranulation, release of superoxide anions, and
cell proliferation. Over-expression of CXCR4 is consid-
ered a key regulatory step in several human malignancies
included breast cancer, resulting in a poor prognosis
[17,18]. In detail, CXCR4 activity was involved in the oes-
trogen resistance of breast cancer [19]. Moreover, high
CXCR4 expression has been related to the metastatic
potential of breast cancer cells, since. in vitro experi-
ments showed that CXCR4 activation by SDF-1 regulates
motility and metastatic potential of neoplastic epithelial
cell lines [20,21], while CXCR4 inhibitors are effective in
reducing chemotactic and metastatic potential of this
receptor [20].
In cats, most studies are focused on the characteriza-
tion of the CXCR4 role associated with FIV infection
[22,23], because of the role of this receptor as mediator
o fv i r u sc e l le n t r y ,a sa l s oo b s e r v e di nh u m a n s[ 2 4 ] .
Conversely, few studies have been targeted on the role
of CXCR4 in feline mammary gland neoplasia [25,26],
although CXCR4 may have a role in development of
mammary carcinoma in cats as in women. Feline mam-
mary tumors show age, incidence, histopathology and
pattern of metastasis similar to human breast cancer
[27]. In addition, the lack of estrogens dependence in
most of these tumours, suggests that this cancer may
represent a suitable animal model for estrogen receptor
(ER) negative breast cancer [28]. Recently, feline mam-
mary carcinoma subtypes have been described to share
features with human inflammatory mammary carcinoma
[29]. At the molecular level HER2 overexpressing malig-
nancies in cats may be considered homologue of the
HER2 positive- poor prognosis-human counterpart [30].
Thus, research in this field may be relevant to better
understand the biology of feline mammary tumour, also
as a comparative model for human breast cancer, and to
evaluate the CXCR4 role in cancer mechanisms. More-
over, immunohistochemistry screening of feline mam-
mary tumours may have interesting applications in
clinical practice as prognostic factor and to evaluate the
possible response to CXCR4 inhibitors.
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e ,b y
immunohistochemistry, the levels of CXCR4 expression
in feline mammary tumours and metastases, and the
proliferative activity induced by SDF-1 on feline carci-
noma primary cultures.
Results
Feline mammary tumours and histological diagnoses
The clinical and pathological data of the feline mammary
carcinomas analysed are summarised in Table 1. The 26
cats under study included 25 domestic short-hairs and
1 persian; 9 were intact females, while 17 were spayed.
The age ranged from 5 to 19 years (median age, 12 years).
In one case the age was not available. Primary malignant
tumours were observed in 24/26 cats (92%), 7/26 animals
beard two neoplastic mammary glands thus we collected a
total of 31 primary tumour samples. Only 2/26 benign
tumours were observed (8%). The primary tumor samples
under evaluation included 14 simple tubulopapillary pri-
mary carcinomas (STPCs), of which four of them gave
metastasis (Table 1). The other samples were diagnosed as
solid carcinomas (SCs, 7 cases) of which one gave lymph
node metastasis, 6 cribriform carcinomas (CCs), 3 simple
tubular carcinomas (STCs) and 1 metastatic adenosqua-
mous carcinoma (ASC). (Table 1). Twenty-seven out of 31
primary malignant lesions were classified as high grade
carcinomas (grade III, 87%) and 4 as intermediate grade
(grade II, 13%). No grade I tumours were observed in this
study. Only 2 benign tumours (1 basaloid adenoma, and
1 complex adenoma) were diagnosed in this group of
animals. Four normal tissue samples, derived from
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Page 2 of 13Table 1 Clinico-pathological features of feline mammary tissues
Cat
n.
Sample
n.*
Sex Age
(yrs)
Breed Histology Grade CXCR4 score
1 1a F 13 DSH STPC II 3+
1b STPC II 1+
2 2 FS 14 DSH STPC III 2+
2M metastasis (adipose tissue) 2+
3 3a FS 7 DSH STPC III 1+
3b STPC III 3+
4 4a FS 15 DSH STPC III 2+
4aM metastasis (lymph node) 3+
4b STPC III 2+
5 5a F 10 DSH STPC III 1+
5b STPC III 2+
5bM metastasis (lymph node) 3+
6 6a FS 12 DSH STPC III 2+
6b STPC III 2+
7 7a F 15 DSH STPC III 2+
7b STPC III 2+
8 8 FS 12 DSH STPC II 3+
8M metastasis (lymph node) 1+
9 9a F 8 DSH SC III 1+
9b SC III 0
10 10 F 14 DSH SC III 2+
11 11 FS 9 DSH SC III 3+
12 12 FS 14 DSH SC III 2+
12M metastasis (lymph node) 3+
13 13 F 10 DSH SC III 3+
14 14 F 5 DSH SC III 1+
15 15 F 19 PC CC III 2+
16 16 FS 13 DSH CC III 3+
17 17 FS 9 DSH CC III 1+
18 18 FS 14 DSH CC III 1+
19 19 FS 9 DSH STC II 2+
20 20 FS n.a DSH STC III 2+
21 21 F 12 DSH STC III 0
22 22 FS 11 DSH CC III 3+
23 23 FS 19 DSH ASC III 2+
23M metastasis (lung) 3+
24 24 FS 12 DSH CC III 2+
25 25 FS 4 DSH BA - 1+
26 26 FS 8 DSH CA - 0
27 27 FS 12 DSH NORMAL (M4 D) - 0
28 28 FS 19 DSH NORMAL (M1 S) - 0
29 29 FS 11 DSH NORMAL (M4 D) - 0
30 30 F 8 DSH NORMAL (M2 S) - 0
F, female, FS, female spayed; DSH, domestic short-hair; PC, persian; STPC, simple tubulopapillary carcinoma; SC, solid carcinoma; STC, simple tubular carcinoma;
CC, cribriform carcinoma; BA, basaloid adenoma; CA, complex adenoma; ASC, adenosquamous carcinoma; n.a., not available. For normal tissues the mammary
gland topography is indicated. *a and b indicate samples from two glands of the same cat, M labels metastatic tissue. Primary tumours and corresponding
metastases of the same cat are reported in bold.
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surgery, were included in the study as CXCR4 expression
reference.
CXCR4 expression in feline mammary carcinomas
The expression of CXCR4, analyzed by immunohisto-
chemistry, was observed in 29 out of 31 (93%) of pri-
mary carcinoma samples (from a total of 24 queens)
although the staining pattern and intensity differed
between tumors as evaluated by CXCR4 scores (1+, 2+
and 3+) reported in Table 1. In 7 out of 24 carcinoma-
bearing animals we analyzed tumors taken from two dif-
ferent mammary glands of the same cat (named as a
and b in Table 1); in this subgroup 4/7 tumors showed
different score of CXCR4 expression among carcinomas
d e r i v e df r o mg l a n daa n dbf r o mt h es a m ec a t ,p o s s i b l y
reflecting heterogeneity across tumour lesions. The
expression of CXCR4 was mostly confined to the mem-
brane and cytoplasm of neoplastic cells (Figure 1) and
differed in intensity and staining pattern (Figure 1,
panels A and B) and among primary (Figure 1, panel B)
and, in most cases, the corresponding metastatic lesions
(Figure 1, panel C). Negative controls and CXCR4 anti-
body specificity were performed as reported in supple-
mentary Figure S1.
To evaluate the specificity of CXCR4 expression in
mammary carcinomas and metastasis, we analyzed the
level of CXCR4 immunopositivity in normal mammary
tissues and benign lesions (1 basaloid adenoma and 1
complex adenoma). As depicted in Figure 2 (panels A
and B), normal mammary gland tissue did not express
detectable level of CXCR4, while epithelial cells of basa-
loid adenoma appeared weakly positive for CXCR4
(CXCR4 score 1+, Figure 2 panel C) in scattered areas
throughout the section, and the complex adenoma was
essentially negative (CXCR4 score 0, Figure 2 panel D).
Figure 3 summarized the distribution of CXCR4 scores
reported in Table 1, among all different grades of
tumours, metastasis and four normal tissues. Box plots
shows the median CXCR4 score for each group: 0 for
normal mammary glands and 0.5+ for benign lesions,
median values increased in grade II and grade III malig-
nant tissues (median sore 2+) while metastases expressed
the highest score. (median value = 3+). By analyzing the
frequency distribution of CXCR4 expression score in the
different groups we observed a statistically significant
association between these two variables (Pearson Chi-
square = 34.96, p = 0.0005).
Interestingly, 4 out of 6 metastatic tumours appeared to
have a stronger CXCR4 expression as compared to the
respective primary tumours (increase of the CXCR4
score, from 2+ to 3+ in cat n. 4, 5,12 and 23, Table 1).
Nevertheless, in two metastatic sites, the neoplastic cells
showed either a lighter immunoreaction if compared
Figure 1 Immunohistochemical analysis of CXCR4 expression in
feline mammary carcinomas. Panel A. Representative primary
feline carcinoma showing a high number of neoplastic cells with
moderate to intense cytoplasmic positivity for CXCR4. (Bar 25 μm).
Panel B. Primary tubulopapillary carcinoma: a poorly differentiated
area with low number of positive neoplastic cells showing a weak
immunoreactivity for CXCR4. (Bar 25 μm). Panel C. Lymph node
metastasis of the feline mammary carcinoma showed in Panel B.
Metastatic cells show a marked immunoreaction for CXCR4 if
compared with the corresponding primary lesion. (Bar 25 μm).
Original magnification 40×.
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changes (cat n.2).
SDF-1/CXCR4 role in primary cultures of feline mammary
carcinoma
To investigate the biological role of CXCR4 expression
in feline mammary carcinoma, fibroblast-free, primary
cell cultures were obtained from 6 primary carcinomas
(cat n. 5, 6, 19, 22, 23 and 24). In vitro feline mammary
cancer cells appeared as adherent monolayers with spin-
dle-like shape (Figure 4, panels A, B, C). The expression
of CXCR4 in each culture was verified by IF staining,
confirming the immunopositivity of mammary carci-
noma primary cells (Figure 4, panels D, E, F), as in the
tissue of origin.
The absence of contaminant fibroblasts, which can
interfere with both immunofluorescence and prolifera-
tion studies, was demonstrated by the lack of pro-col-
lagen expression in the mammary carcinoma cell
cultures, while isolated tumour fibroblasts, used as posi-
tive controls, showed a strong staining (Figure 4, upper
panels).
Beside CXCR4 expression, a phenotypic characteriza-
tion of the cells from the primary cultures was per-
formed, by analyzing the expression of common
mammary lineage markers (CK14, CK18, EMA, ER-a), or
proteins (EGFR and HER-2/neu) overexpressed in mam-
mary carcinoma conferring malignant behaviour (Figure
5). As expected, feline mammary carcinoma cells from all
tumour tested, homogeneously expressed the mammary
epithelial marker EMA. Moreover, in vitro cultures abun-
dantly expressed CK14 (100% of cultures) and, in variable
proportion of cells, CK18 (83% of cultures). In addition,
we include the evaluation of ER-a immunocytofluores-
cence to define its pattern of expression in feline mam-
mary cancer cells, detecting different levels of positivity,
but generally low or weak (60% of immunopositivity). As
far as HER2/neu and EGFR expression in feline primary
cultures, both proteins were expressed in all mammary
carcinoma cultures. Representative results from immuno-
cytofluorescence are reported in Figure 5, including the
CXCR4 positivity.
In order to analyze the proliferative effects induced by
CXCR4 activation, the obtained mammary carcinoma
Figure 2 Immunohistochemical analysis of CXCR4 expression in normal feline mammary gland and benign lesions. Panel A.
Representative photomicrograph of a normal lobule of feline mammary gland tissue showing CXCR4 negativity (Bar 50 μm, original
magnification 20×). Panel B. Detail of the normal lobule of feline mammary gland tissue showing several CXCR4-negative acini, (Bar 25 μm,
original magnification 40×). Panel C. Feline benign mammary lesion (basaloid adenoma, cat n. 25): epithelial cells show negative or weak
immunoreaction for CXCR4 (Bar 25 μm, original magnification 40×). Panel D. Feline benign mammary lesion (complex adenoma, cat n. 26):
negative immunoreaction for CXCR4. (Bar 25 μm, original magnification 40×).
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25 nM SDF-1 for further 24 h (the concentration was
chosen as the maximal growth stimulatory effect
obtained in previous experiments on human breast can-
cer cell lines [19]), and then MTT cell viability assays
were performed. SDF-1 exposure induced a statistically
significant proliferative stimulus in 5 out of 6 feline
mammary cultures as compared to serum-starved
untreated controls, with a mean increase of cell growth
of +30%, p < 0.05 (Figure 6A). To discriminate the level
of growth-arrest induced by serum deprivation, in a sub-
group of 3 cultures the SDF-1 stimulus was compared
to complete medium (10% FCS) effects: serum was able
to significantly recover the proliferative rate of cells of
about +50% over the corresponding starved cultures.
Thus, SDF-1 significantly promotes feline mammary car-
cinoma cell growth, although with individual differences
among cultures from different tumors, that is in the
same order of magnitude, although lower, than that
induced by FCS. To characterize the mitogenic effects of
SDF-1, a dose-response curve (25, 50 and 100 nM) was
performed in one primary culture (cat n. 22). The che-
mokine showed a dose-dependent effect with all the
concentrations tested able to induce a significant growth
stimulation, that was maximal at 100 nM.
To demonstrate that SDF-1 effects occurred through
CXCR4 expressed in feline mammary carcinoma cells, we
exposed cells to the CXCR4 antagonist AMD3100.
AMD3100 pre-treatment, was able to revert the SDF-1
increase in cell proliferation, confirming that CXCR4 is
mediating SDF-1 effects in these cells. In addition, we
observed that AMD3100 significantly inhibits basal cell
growth, possibly implying the occurrence of a constitu-
tive role of CXCR4 in cell proliferation.
Discussion
Several studies demonstrated that: a) the expression of
chemokine receptors in neoplastic cells is not random; b)
CXCR4 is the most widely expressed chemokine receptor
in most tumours; c) the effects of SDF-1 on CXCR4-
expressing cancer cells are pleiotropic [31]. In particular,
SDF-1/CXCR4 axis is enrolled in many functional aspects
of tumour progression, such as angiogenesis, site-specific
metastasization, proliferation and survival of neoplastic
cells [2,32]. It is also recognized that metastastic beha-
viour of cancer cells may be reinforced by hypoxia, a con-
dition that induce up-regulation of CXCR4 expression
mediated by hypoxia-inducible factor-1a (HIF-1a)
[33,34]. SDF-1/CXCR4 axis is involved in the promotion
of angiogenesis, local cell proliferation and migration of
cancer cells to the metastatic sites in many different
kinds of cancers as those of breast [21,35], lung [36],
ovarian [1,37], renal [38], prostate [39], and neuroblas-
toma [40]. Moreover, it seems relevant to remind that
CXCR4 expression has been associated to a worse prog-
nosis in human tumours, and then, in the future, it could
be also used as prognostic indicator [41].
In contrast with the large number of studies in human
oncology, there are only few scientific articles supporting
the role of SDF-1/CXCR4 axis in spontaneous tumours
of domestic animals. Tanabe and colleagues [26]
observed that the receptor’s mRNA is not identifiable in
mammary tissue of healthy cats. However, they found
CXCR4 mRNA in area adjacent to necrotic tissue, sur-
rounding blood vessels and in cells infiltrating the lym-
phatic tissue in 72.3% of 65 samples. In the same study,
the authors observed a statistically significant relationship
between infiltration of neoplastic cells in lymphatic and
CXCR4 expression [26], although no relationship was
observed between CXCR4 expression and one-year survi-
val time of the cats included in the study [26]. In another
study, higher expression of CXCR4 mRNA in metastatic
cells as compared with cells from primary tumours was
reported, altogether with the observation that neoplastic
cells from feline mammary carcinomas express more
CXCR4 than non-neoplastic mammary tissues [25].
I nt h ep r e s e n ts t u d yw ed e m o n s t r a t e d ,f o rt h ef i r s t
time, a high CXCR4 expression in several feline high
grade mammary carcinoma, evaluated at protein level by
immunohistochemistry. Interestingly, although the lim-
ited number of benign and metastatic lesions, but includ-
ing normal tissues, we observed a statistically significant
Figure 3 CXCR4 score in feline mammary carcinomas. Box plots
represent the distribution of CXCR4 score in different feline
mammary carcinoma histological types. A statistically significant
relationship (Pearson’s Chi sqr. test) was observed between the
increase of CXCR4 scores from normal to benign, malignant and
metastatic mammary tissues. Each box shows the median, quartiles,
and extreme values within a group.
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Page 6 of 13correlation between CXCR4 score levels and the increase
of tumor grade or metastases. However, without drawing
a definitive conclusion due to the need of higher num-
bers, the present results showing absence or low CXCR4
expression in normal and benign mammary tissues may
suggest a specificity of CXCR4 expression for mammary
carcinomas and metastases.
As far as the malignant primary tumours CXCR expres-
sion, although we observed some variability in the inten-
sity of the anti-CXCR4 immunoreaction, only occasionally
we detected variation in the percentage of positive cells.
Moreover, although a large number of samples will be
required to perform an appropriate statistical analysis, in
this study the majority of metastastic lesions (5/6) dis-
played a higher expression compared to cells within the
respective primary lesion. These observations, at least in
part, support the results reported in the literature for
breast cancer in women and in feline mammary carcinoma
[42].
The interest in researching on SDF-1/CXCR4 pathways
is also oriented to discover ‘new chemical entities’ able to
block this mechanism and specifically inhibit CXCR4
functions. Actually, there are some examples published
in the international literature reporting the possible use
of CXCR4 inhibitors. The latter have been used to reduce
growth and metastasis of head and neck cancers and
intracranial growth of brain tumours [43,44]. These
results have been also supported by in vitro experiments
that proved the efficacy of CXCR4 inhibitors in blocking
SDF-1/CXCR4-mediated proliferation and migration in
breast cancer and lymphoblastic leukaemia [19,45]. In
veterinary oncology, Oonuma and collaborators [25]
Figure 4 CXCR4 expression in primary cultures of feline mammary carcinoma. Upper panels. Representative immunofluorescence staining
using anti-procollagen I (red) of fibroblast and purified feline mammary carcinoma primary cultures, after immunomagnetic fibroblast separation.
DAPI-counterstained nuclei in blue. No fibroblast contamination is observed in the tumor cell cultures. Lower panel. A-B-C. Phase-contrast
microscopy observation of the cultured cells derived from feline mammary gland tumours with an epithelioid morphology with some elongated
spindle-shaped cells growing in monolayer (original magnification 10×) Panels D-E-F: immunofluorescence detection of CXCR4 expression (red)
in primary cultures (DAPI-counterstained nuclei in blue). Original magnification 20×.
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Page 7 of 13Figure 5 Immunofluorescence analysis of primary cultures for mammary malignant epithelial cell markers. Cells were stained with
relevant markers (CK14, CK18, EMA, ER-a) for epithelial mammary cells frequently over-expressed proteins in malignant mammary tumors (HER2/
neu, EGFR): immunopositivity demonstrates the presence in feline primary carcinoma cultures the presence of malignant epithelial mammary
cells. Representative confocal microscopy images are reported. Bar 25 μM, original magnification 60×.
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mammary carcinoma cell lines incubated with CXCR4
antagonists.
Here, besides the expression of CXCR4 in feline
mammary tumours, we also investigated the functional
role of this receptor in mediating proliferative signals.
In vitro,5o u to f6a n a l y z e dp r i m a r yc u l t u r e so fm a m -
mary carcinoma cells showed significant increased cell
proliferation in response to CXCR4 activation by
nanomolar concentrations of SDF-1. The effect was
quantitatively variable but reached, on the average a
values similar to that induced by FCS, thus confirming
that SDF-1/CXCR4 axis is an important signalling
pathway involved in feline mammary cell proliferation.
Interestingly, the use of the CXCR4 antagonist
AMD3100, while confirming the specificity of SDF-1
effects in vitro through CXCR4, showed a reduction
also in basal proliferation rate. Thus, it could be
hypothesized that a basal SDF-1 secretion leads to
autocrine CXCR4 activation in some tumor cell cul-
ture. This observation may also explain why in few
cultures a lower proliferation is induced by exogenous
SDF-1 that could be masked by the autocrine CXCR4
activation. A similar different response, related to con-
stitutive autocrine SDF-1 effect, was recently demon-
strated in human pituitary adenoma cell cultures in
vitro [46,47]. A larger number of tumors have to be
analysed to confirm this hypothesis.
These data, although preliminary, strongly suggest
that CXCR4 activity controls mammary carcinoma cell
proliferation in cats as it does in humans, and propose
that pharmacological inhibition of this receptor may
represent an innovative approach for this kind of
tumours. Moreover, our data propose that primary
feline can reflect and maintain in vitro the phenotype
of epithelial malignant carcinoma mammary cells and
are potential suitable experimental models for assessing
the biological activity of novel molecules with antitu-
mour effects.
In the past, several studies reported the relevance of natu-
rally occurring cancers in domestic animals as model for
study human cancer biology and translational therapeutics
[48,49]. Among other tumours, mammary carcinomas
show a relatively high similarity with the human counter-
part as far biological behaviour, clinical course and
responses to cytotoxic agents. The development of in vitro
models of feline mammary carcinomas may represent a
relevant tool to identify novel molecular pharmacological
targets to be used in veterinary setting and possibly
extended to humans.
Conclusions
With the increase in the development of novel therapeu-
tic agents feline mammary carcinomas can provide a
useful model to test new drugs, as far as efficacy and
toxicity, including novel CXCR4 antagonists.
In conclusion, our results suggest that routine evalua-
tion of CXCR4 in feline mammary neoplastic lesions
might be useful for selection of cases which may be
treated with targeted chemotherapy. However, further
investigations are required to better evaluate the poten-
tial role of CXCR4 as prognostic factor and as a target
for novel chemotherapeutic agents.
Figure 6 SDF-1 growth stimulation on feline mammary
carcinoma primary cultures. A. Scatterplot represents the
individual and mean values of increase of growth rate in 6 primary
cultures stimulated with SDF-1 (25 nM) or 10% FCS for 24 h,
evaluated by MTT assay. *P < 0.05, **P < 0.01 (vs. serum-starved
control). B. Dose-response curve of SDF-1 treatment for 24 h. *P <
0.05, **P < 0.01 (vs. untreated serum- starved control) evaluated by
MTT assay. C. Effects of CXC4 inhibition by the antagonist AMD3100
on SDF-1 cell growth stimulation evaluated by MTT assay. Cells
were treated with SDF-1 (25 nM) for 24 h in the absence or
presence of AMD3100 (10 μM). AMD3100 significantly reverts SDF-1
growth stimulus and affects basal proliferation. **P < 0.01 (vs.
untreated serum- starved control).
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Tumor samples and tissue processing
Twenty-six animals were included in this study. Feline
mammary lesions (n = 33) and metastasis (n = 6) col-
lected at the time of surgical excision, were obtained
from the histopathology service of the National Reference
Centre for Veterinary and Comparative Oncology of the
“Istituto Zooprofilattico Sperimentale del Piemonte,
L i g u r i aeV a l l eD ’Aosta” of Genova, Italy. Four normal
mammary tissue samples were obtained from unaffected
glands resected during tumor surgery.
All the collected tissues were fixed in 10% buffered
formalin and embedded in paraffin. Tissue sections (3
μm) were stained by standard haematoxylin and eosin
methods for histological examination and classified
according to the World Health Organization (WHO)
Histological Classification of Mammary Tumors of the
Dog and Cat [50]. Histological grade was defined
accordingly to the histological grading system of canine
and feline mammary carcinoma [51]. Briefly, histological
grade was defined taking account of tubule formation
(from 1 point if the tissue section has well-marked
tubule formation to 3 points if there are very few or no
tubules), hyperchromatism and mitoses (1 point if only
an occasional hyperchromatic or mitotic figures per
high-power field are seen; 2 points if there are two or
three such figures, and 3 points if the number is higher),
and irregular size and shape of nuclei (from 1 point if
nuclei are fairly uniform in size, shape and staining and
3 points if pleiomorphism is marked). Finally, the score
of all three components (tubule formation, mitotic
count, and nuclear pleiomorphism), were added together
to give the grade. The combined histological grade with
final scores of 3-5 were designed grade I or low grade
tumours, scores of 6 or 7 were classified grade II or
intermediate grade tumours, and 8 or 9 were classified
as grade III or high grade tumours.
Immunohistochemistry
Immunohistochemical analysis was performed using a rab-
bit anti-CXCR4 antibody (C3116, Sigma-Aldrich, Milano.
Italy). Tissue sections (3 μm) were deparaffinized in
xylene, rehydrated in a graded series of ethanol solutions,
placed in Coplin jars containing a citrate solution 1:10 in
distilled water (Target Retrieval Solution, citrate pH 6.0,
Dako Cytomation, Glostrup, Denmark) and heated in a
water bath at 98°C for 20 min to unmask the antigen.
After the eating step, slides were allowed to cool for 15
min under running water and washed with a solution 1:10
of Tris-buffered saline (TBS) in distilled water (TBS solu-
t i o n ,1 0 × ,p H7 . 4 ,B i o p t i c a ,M i l a n o ,I t a l y ) .E n d o g e n o u s
peroxidase activity was quenched by immersion in solu-
tion of 3% hydrogen peroxide in distilled water for 30 min,
followed by several rinses in TBS. Non-specific binding
was blocked by incubation with 5% bovine serum albumin
(BSA, Albumin Fraction V, pH 7.0, Applichem, Darmstadt,
Germany) in TBS for 30 minutes at r.t. Slides were incu-
bated overnight with anti-CXCR4 diluted 1:500 in Anti-
body Diluent with Background reducing Components
(Dako North America Inc., Carpinteria, CA, USA). The
slides were rinsed in TBS (two times for 4 min) and then
incubated with secondary antibody REAL Envision Detec-
tion System Peroxidase/DAB+, mouse/rabbit (Dako)
according to the manufacturer’s instruction. The slides
were rinsed in TBS (two times for 4 min) and then stained
with 3-3’-diaminobenzide tetrahydrochloride accordingly
with manufacture’s instruction. Sections were counter-
stained with Mayer’s haematoxylin solution. Negative con-
trols were run in parallel, substituting the primary
antibody with 5% BSA in TBS or rabbit IgG (Sigma-
Aldrich, see Supplementary Figure S1, panel A and B,
respectively). To verify the specificity and cross-reactivity
of the rabbit-anti CXCR4 antibody for feline mammary tis-
sues, in some cases we run parallel immunohistochemical
staining with the Monoclonal Mouse IgG2B CXCR4 anti-
body from R&D Systems, (Minneapolis, MN, USA) that
we also used in immunofluorescence experiments and
cross-reacts with both human and feline CXCR4 (Supple-
mentary Figure S1, C panel D show the comparison
between the 2 antibodies). As positive control, 10% neu-
tral-buffered formalin fixed tissue sections of human
breast carcinoma were used (data not shown). Tissue sec-
tions were evaluated by light microscopy (Nikon Cool-
scope, Nikon, Firenze, Italy) to determine CXCR4
immunoreaction and the cellular localization of positive
immunolabelling. Both intensity of the resulted immunor-
eaction and percentage of positive cells were evaluated
taking into account previous experiences published by two
different authors [52,53]. Tumour cells with brown cyto-
plasm were considered positive and staining intensity was
classified as: weak brown (1+); moderate brown (2+) and
strong brown (3+). Percentage of stained tumour cells,
obtained evaluating at least 1000 neoplastic cells in 10
high-power fields for each tissue section, was categorized
into four classes: 0 = negative, 1 = < 10%; 2 = 10-50%; 3 =
> 50%. Multiplication of intensity and percentage scores
(staining index) was utilized to determine the following
results: 0, 1, 2, 3, 4, 6, and 9. The final results were then
categorized as 0, 1+, 2+ and 3+ as reported below:
a. Staining index 0: (0 = 0) and 1(1 × 1 = 1) were con-
sidered negative (0)
b. Staining index 2: (2 × 1 = 2) and 3 (3 × 1 = 3) were
considered (1+)
c. Staining index 4: (2 × 2 = 4) and 6 (2 × 3 = 6) were
considered (2+)
d. Staining index 9: (3 × 3 = 9) was considered (3+)
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Tumor cells were isolated from 6 primary feline mam-
mary carcinomas (Table 1, cat n. 5, 6 and, 19, 22, 23
and 24) immediately after surgical removal. A portion of
fresh tumour tissue was excised and saved in sterile
tubes with D-MEM medium (Lonza, Verviers, Belgium)
supplemented with penicillin/streptomycin (200 U/ml;
Lonza), amphotericin B (250 ng/ml, Sigma-Aldrich) to
avoid bacterial and fungi contamination. Samples were
washed PBS to eliminate blood and debris eventually
present, dissected to take off skin or other non-tumour
tissues and mechanically disaggregated. Cell suspension
was filtered through a 70 μm cell mesh (BD Biosciences,
Bedford, MA, USA) recovering single cells by centrifuga-
tion. The isolated cells were seeded into T25 flasks in
D-MEM culture medium containing 10% FCS, 100 U/ml
penicillin/streptomycin and 2 mM glutamine (Lonza).
To avoid fibroblast contamination and overgrowth in
culture, FMC cells were purified by immunomagnetic
separation with anti-fibroblast microbeads (MACS, Mil-
tenyi Biotec, Bologna, Italy) as reported [54]. Pro-col-
lagen (anti-procollagen type I, SP1.D8, Developmental
Studies Hybridoma Bank, Iowa City, IA, USA) immuno-
fluorescent staining was performed to verify the absence
of fibroblast contamination and overgrowth in culture.
Exemplificative images of the absence of fibroblast con-
tamination in mammary tumour cells are reported in
Figure 4 (upper panel). Cells were maintained at 37°C in
a humidified incubator at 5% CO2. Individual culture
flasks were observed daily and photographed by a
phase-contrast microscope for the presence of cell
monolayers and morphologies.
Immunocytofluorescence
Immunofluorescence (IF) detection was performed as
reported [46]. Briefly, feline mammary carcinoma cells
were grown on coverslips, fixed with 4% paraformalde-
hyde in PBS and stained with CXCR4 (R&D Systems,
Minneapolis, MN, USA), epithelial membrane antigen
(EMA), cytokeratins 14 (CK14) and 18 (CK18), ER-a,
Her2/neu (Dako), EGFR (Cell Signaling, Beverly, MA,
USA). Cells were labelled with fluorochrome-conjugated
secondary antibody (red-fluorescent Alexa Fluor 568 or
green-fluorescent Alexa Fluor 488 dyes, Molecular
Probes Invitrogen, Milano, Italy) for 1 h, nuclei were
counterstained with 4’,6-diamidino-2-phenylindole
(DAPI, Sigma-Aldrich) and mounted with Mowiol. Nega-
tive controls were included in the experiments by omit-
ting the primary antibodies. IF slides were visualized and
photographed with a DM2500 microscope (Leica Micro-
systems, Wetzlar, Germany) equipped with a DFC350FX
digital camera (Leica Microsystems) or confocal laser
scanning microscopy (Bio-Rad MRC 1024 ES).
MTT assay
Cell viability was determined by the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich) [55]. After seven days in vitro to
expand the culture, cells were seeded in 24-well plates
in complete medium, serum-starved for 24 h and then
treated with 25 nM SDF-1 (Immunological Sciences,
Roma, Italy) or 10% FCS for further 24 h. The
AMD3100 (Sigma-Aldrich) CXCR4 antagonist was
added to cultures at 10 μM for 24 h in the presence or
absence of SDF-1. MTT solution (0.25 mg/ml in PBS,
final concentration) was added for 4 h at 37°C. optical
density (O.D.) was measured spectrophotometrically at
570 nm. Data are expressed as mean ± S.D. and referred
to the 100% value of serum-starved control samples.
Statistical analysis
Statistical analysis was performed with SPSS 9.0 software
(SPSS Inc., Chicago, USA) using ANOVA, cross-tabula-
tion and Pearson chi-square test, when appropriate.
P ≤ 0.05 was accepted as statistically significant.
Additional material
Additional file 1: Figure S1 Immunohistochemical controls for
CXCR4 expression in feline mammary carcinomas. A. Negative
control obtained by omitting the rabbit primary antibody against CXCR4.
B. Negative control obtained by substituting the primary antibody with
rabbit IgG. C. CXCR4 staining with rabbit anti-CXCR4 antibody (Sigma-
Aldrich). D. CXCR4 staining with rabbit anti-CXCR4 antibody (R&D
Systems). Tissue images derived from a tubulopapillary carcinoma, bar =
25 microm, original magnification 40×.
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